ArticleViruses2024
Phage Therapy in a Burn Patient Colonized with Extensively Drug-Resistant
Article in Viruses, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Approaching the post-antibiotic era: phage therapy current practices and future horizons.mBio · 2026Review
- Phage Therapy as an Alternative Strategy Against Pseudomonas aeruginosa: A Narrative Review of Preclinical and Clinical Evidence.MicrobiologyOpen · 2026Review
- Phage Therapy in Combating Multidrug-Resistant Gram-Negative Pathogens: A Scoping Review.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Drug-Resistant Infections in Burn Patients: A One-Year Analysis of Microbiological Trends and Predictive Risk Factors in a Romanian Tertiary Care Centre.Antibiotics (Basel, Switzerland) · 2026Article
- A temperate phage encoding a catalytically active endolysin: characterization of phage P7869 and its Lys7869 against Pseudomonas aeruginosa.BMC microbiology · 2026Article
- A comprehensive analysis of the kinetics of infection of lytic bacteriophages specific to the ESKAPE and critical pathogens.World journal of microbiology & biotechnology · 2026Review
- A broad-host-range inhalable phage cocktail for treatment of multidrug-resistantFrontiers in cellular and infection microbiology · 2026Article
- Characterisation of a NovelPathogens (Basel, Switzerland) · 2025Article
- Biocontrol of Phage Resistance inViruses · 2025Review
- Healthcare-Associated Infections: The Role of Microbial and Environmental Factors in Infection Control-A Narrative Review.Infectious diseases and therapy · 2025Review
- Phage Therapy as a Rescue Treatment for RecurrentViruses · 2025Article
- Rational design of an epitope-centric vaccine againstFrontiers in immunology · 2025Article
- Phage therapy as a revitalized weapon for treating clinical diseases.Microbiome research reports · 2025Review
- Multidrug-resistantFrontiers in microbiology · 2025Review
- Phage diversity in One Health.Essays in biochemistry · 2024Review
- A New Insight into Phage Combination Therapeutic Approaches Against Drug-Resistant Mixed Bacterial Infections.PHAGE (New Rochelle, N.Y.) · 2024Review
- Article
- Reappraising traumatic brain injury and ventilator-associated pneumonia through the brain-lung-immune-microbiome axis.Frontiers in neurologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.